Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Pivot X, Romieu G, Debled M, Pierga JY, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 2019 Jun 6. pii: S0140-6736(19)30653.
PMID: 31178155


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016